1
|
Spiric J, Schulenborg T, Holzhauser T, Schuler F, Bonertz A, Lauer I, Bartel D, Vieths S, Mahler V, Reuter A. Quality control of allergen products with mass spectrometry part I: Positioning within the EU regulatory framework. Allergy 2024. [PMID: 38425053 DOI: 10.1111/all.16080] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/25/2023] [Revised: 01/25/2024] [Accepted: 02/18/2024] [Indexed: 03/02/2024]
Abstract
Mass spectrometry (MS) has advanced greatly and many of its applications are ready for utilization within regulatory procedures and could significantly contribute to overcome challenges in standardization of allergen products. It seems sensible to discuss MS within the regulatory framework, before addressing technical questions. While the application to purified proteins is well established from product development to manufacturer's release analytics, its application to complex products such as allergen products is still under development. It needs to be determined where it can complement or replace established methods or where MS offers limited improvement. Despite its technical appeal and versatility, currently MS is mentioned in regulatory guidelines only as one possible measurement method. For example, no specific MS method is given in the European Pharmacopoeia. We discuss applications of MS within the EU regulatory framework. This includes their advantages and disadvantages and their positioning between research, characterization, manufacturer's release analytics and official batch testing. We discuss the qualitative detection of single and multiple allergens as proof of identity, qualitative to semi-quantitative protein profiles for batch to batch consistency testing, and quantification of allergens to state mass units of allergens. MS may also facilitate standardization of allergen products, reference products and reference standards.
Collapse
Affiliation(s)
- Jelena Spiric
- Allergology Division, Central Method Development Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Thomas Schulenborg
- Allergology Division, Central Method Development Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Thomas Holzhauser
- Allergology Division, Central Method Development Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Frank Schuler
- Allergology Division, Allergology Quality Assessment Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Andreas Bonertz
- Allergology Division, Allergology Quality Assessment Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Iris Lauer
- Allergology Division, Allergology Quality Assessment Section, Paul-Ehrlich-Institut, Langen, Germany
| | - Detlef Bartel
- Allergology Division, Allergens Product Testing Section, Paul-Ehrlich-Institut, Langen, Germany
| | | | - Vera Mahler
- Allergology Division, Paul-Ehrlich-Institut, Langen, Germany
| | - Andreas Reuter
- Allergology Division, Central Method Development Section, Paul-Ehrlich-Institut, Langen, Germany
| |
Collapse
|
2
|
Ziegler A, Olzhausen J, Hamza E, Stojiljkovic A, Stoffel MH, Garbani M, Rhyner C, Marti E. An allergen-fused dendritic cell-binding peptide enhances in vitro proliferation of equine T-cells and cytokine production. Vet Immunol Immunopathol 2021; 243:110351. [PMID: 34800874 DOI: 10.1016/j.vetimm.2021.110351] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/02/2021] [Revised: 10/26/2021] [Accepted: 11/05/2021] [Indexed: 01/25/2023]
Abstract
Allergen-specific immunotherapy (AIT) constitutes the only curative approach for allergy treatment. There is need for improvement of AIT in veterinary medicine, such as in horses suffering from insect bite hypersensitivity, an IgE-mediated dermatitis to Culicoides. Dendritic cell (DC)-targeting represents an efficient method to increase antigen immunogenicity. It is studied primarily for its use in improvement of cancer therapy and vaccines, but may also be useful for improving AIT efficacy. Immunomodulators, like the Toll-like receptor 4 (TLR-4) agonist monophosphoryl lipid-A (MPLA) has been shown to enhance the IL-10 response in horses, while CpG-rich oligonucleotides (CpG-ODN), acting as TLR-9 agonists, have been shown to induce Th1 or regulatory responses in horses with equine asthma. Our aim was to evaluate in vitro effects of antigen-targeting to equine DC with an antigen-fused peptide known to target human and mouse DC and investigate whether addition of MPLA or CpG-ODN would further improve the induced immune response with regard to finding optimal conditions for equine AIT. For this purpose, DC-binding peptides were fused to the model antigen ovalbumin (OVA) and to the recombinant Culicoides allergen Cul o3. Effects of DC-binding peptides on cellular antigen uptake and induction of T cell proliferation were assessed. Polarity of the immune response was analysed by quantifying IFN-γ, IL-4, IL-10, IL-17 and IFN-α in supernatants of antigen-stimulated peripheral blood mononuclear cells (PBMC) in presence or absence of adjuvants. Fusion of DC-binding peptides to OVA significantly enhanced antigen-uptake by equine DC. DC primed with DC-binding peptides coupled to OVA or Cul o3 induced a significantly higher T-cell proliferation compared to the corresponding control antigens. PBMC stimulation with DC-binding peptides coupled to Cul o3 elicited a significant increase in the pro-inflammatory cytokines IFN-γ, IL-4, IL-17, as well as the anti-inflammatory IL-10, but not of IFN-α. Adjuvant addition further enhanced the effect of the DC-binding peptides by significantly increasing the production of IFN-γ, IL-4, IL-10 and IFN-α (CpG-ODN) and IL-10 (MPLA), while simultaneously suppressing IFN-γ, IL-4 and IL-17 production (MPLA). Targeting equine DC with allergens fused to DC-binding peptides enhances antigen-uptake and T-cell activation and may be useful in increasing the equine immune response against recombinant antigens. Combination of DC-binding peptide protein fusions with adjuvants is necessary to appropriately skew the resulting immune response, depending on intended use. Combination with MPLA is a promising option for improvement of AIT efficacy in horses, while combination with CpG-ODN increases the effector immune response to recombinant antigens.
Collapse
Affiliation(s)
- Anja Ziegler
- Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Länggassstrasse 124, CH-3001 Bern, Switzerland.
| | - Judith Olzhausen
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Herman-Burchardstrasse 9, CH-7265 Davos Wolfgang, Switzerland
| | - Eman Hamza
- Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Länggassstrasse 124, CH-3001 Bern, Switzerland; Department of Zoonoses, Faculty of Veterinary Medicine, Cairo University, Egypt
| | - Ana Stojiljkovic
- Division of Veterinary Anatomy, Vetsuisse Faculty, University of Bern, Länggassstrasse 120, CH-3001 Bern, Switzerland
| | - Michael H Stoffel
- Division of Veterinary Anatomy, Vetsuisse Faculty, University of Bern, Länggassstrasse 120, CH-3001 Bern, Switzerland
| | - Mattia Garbani
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Herman-Burchardstrasse 9, CH-7265 Davos Wolfgang, Switzerland
| | - Claudio Rhyner
- Swiss Institute of Allergy and Asthma Research (SIAF), University of Zürich, Herman-Burchardstrasse 9, CH-7265 Davos Wolfgang, Switzerland
| | - Eliane Marti
- Division of Neurological Sciences, Vetsuisse Faculty, University of Bern, Länggassstrasse 124, CH-3001 Bern, Switzerland
| |
Collapse
|